-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Unicycive Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2020 to Q3 2025.
- Unicycive Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $1.33M, a 38.2% decline year-over-year.
- Unicycive Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was -$1.86M, a 130% decline year-over-year.
- Unicycive Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was -$4.61M, a 52.8% increase from 2023.
- Unicycive Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$9.77M, a 162733% decline from 2022.
- Unicycive Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$6K, a 99.4% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)